InnoCan Pharma Corporation (INNO.CN)
| Previous Close | 0.2500 |
| Open | 0.2550 |
| Bid | 0.2550 x N/A |
| Ask | 0.2700 x N/A |
| Day's Range | 0.2550 - 0.2550 |
| 52 Week Range | 0.1950 - 0.6800 |
| Volume | |
| Avg. Volume | 31,672 |
| Market Cap | 63.653M |
| Beta (5Y Monthly) | 3.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0750 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Innocan Pharma Reports Successful Results of Efficacy Test for Vaginal Derma Product
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 23, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its vaginal derma product (the "Product").The results of the Trial demonstrate that Innocan's Product, which contains cannabinoids, phytoestrogens, h
- Baystreet
Stocks in play: InnoCan Pharma Corp
Announces the launch of its licensing and commercialization strategy work with respect to cannabinoid ...
- Newsfile
Innocan Pharma Announces Launch of CBD Veterinary Commercialization Team
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 17, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is excited to announce the launch of its licensing and commercialization strategy work with respect to cannabinoid (CBD) therapy in the veterinary field.Innocan CEO, Iris Bincovich, s
